bPiDI: a novel selective α6β2* nicotinic receptor antagonist and preclinical candidate treatment for nicotine abuse.
| Author | |
|---|---|
| Abstract |
:
Nicotinic acetylcholine receptors (nAChRs) containing α6β2 subunits expressed by dopamine neurons regulate nicotine-evoked dopamine release. Previous results show that the α6β2* nAChR antagonist, N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB) inhibits nicotine-evoked dopamine release from dorsal striatum and decreases nicotine self-administration in rats. However, overt toxicity emerged with repeated bPiDDB treatment. The current study evaluated the preclinical pharmacology of a bPiDDB analogue. |
| Year of Publication |
:
2011
|
| Journal |
:
British journal of pharmacology
|
| Volume |
:
163
|
| Issue |
:
2
|
| Number of Pages |
:
346-57
|
| ISSN Number |
:
0007-1188
|
| URL |
:
https://doi.org/10.1111/j.1476-5381.2011.01220.x
|
| DOI |
:
10.1111/j.1476-5381.2011.01220.x
|
| Short Title |
:
Br J Pharmacol
|
| Download citation |
